Helen Mackay - Concepedia

Author

Helen Mackay

Also Known As

Erkki Koivunen, G Allo, Gulley, Margaret L., H J Mackay, H MacKay, H Mackay, H. J. MACKAY, H. J. MacKay, H. J. Mackay, H. MACKAY

333

Publications

12.9K

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto Sunnybrook Health Science Centre University Health Network Health Sciences Centre

About

Helen Mackay is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	55	5.8K
2	Health Sciences	7	7	592
3	Public Health	4	4	119
4	Education	1	1	10
5	Engineering	1	1	10

Helen Mackay

101

Publications

9.5K

Citations

H-Index

Page 1

	Year	Citations
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Karen A. Gelmon, Marc Tischkowitz, Helen Mackay, The Lancet Oncology Breast OncologyMedicineGynecologyBreast CancerTriple-negative Breast Cancer	2011	1.1K
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell, Journal of Clinical Oncology	2020	777
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, The Lancet Oncology MedicineRandomised Phase 2GynecologyCancer TreatmentOncology	2014	540
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type Leora Witkowski, Jian Carrot‐Zhang, Steffen Albrecht, Nature Genetics Somatic Smarca4 MutationsSomatic VariantHypercalcemic TypeSmall Cell CarcinomaGynecology	2014	489
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative Ellen Stelloo, Tjalling Bosse, Remi A. Nout, Modern Pathology Targetable PathwaysTransportec InitiativeHigh-risk Endometrial CancerMedicineCancer Management	2015	476
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study Weiva Sieh, Martin Köbel, Teri A. Longacre, The Lancet Oncology Ovarian Cancer SurvivalMedicineHormonal ReceptorPathologyGynecology	2013	423
<i>HER2</i> Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology Angela N. Bartley, M. Kay Washington, Carol Colasacco, Journal of Clinical Oncology Esophageal CancerGastroenterologyPathologyTumor BiologyOptimal Her2 Testing	2017	398
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group Amit M. Oza, Laurie Elit, Ming‐Sound Tsao, Journal of Clinical Oncology	2011	333
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology Angela N. Bartley, M. Kay Washington, Christina B. Ventura, Archives of Pathology & Laboratory Medicine	2016	240
Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors Kim Appleton, Helen Mackay, Ian Judson, Journal of Clinical Oncology	2007	228

Page 1